Novel targeted agents and the need to refine clinical end points in chronic lymphocytic leukemia.
作者信息
Cheson Bruce D, Byrd John C, Rai Kanti R, Kay Neil E, O'Brien Susan M, Flinn Ian W, Wiestner Adrian, Kipps Thomas J
机构信息
Lombardi Comprehensive Cancer Center, Georgetown University Hospital, Washington, DC, USA.
出版信息
J Clin Oncol. 2012 Aug 10;30(23):2820-2. doi: 10.1200/JCO.2012.43.3748. Epub 2012 Jul 9.
Abstract
摘要
相似文献
1
Novel targeted agents and the need to refine clinical end points in chronic lymphocytic leukemia.新型靶向药物与优化慢性淋巴细胞白血病临床终点的必要性。
J Clin Oncol. 2012 Aug 10;30(23):2820-2. doi: 10.1200/JCO.2012.43.3748. Epub 2012 Jul 9.
2
Targeted Agents for the Frontline Management of Chronic Lymphocytic Leukemia.慢性淋巴细胞白血病一线治疗的靶向药物
Clin Adv Hematol Oncol. 2016 May;14(5 Suppl 8):7-12.
3
Hepatitis B Virus Reactivation under Ibrutinib Treatment in a Patient with Chronic Lymphocytic Leukemia.依鲁替尼治疗慢性淋巴细胞白血病患者过程中出现的乙型肝炎病毒再激活
Turk J Haematol. 2020 Aug 28;37(3):208-209. doi: 10.4274/tjh.galenos.2020.2019.0180. Epub 2020 Apr 6.
4
Prognostic models in chronic lymphocytic leukemia patients receiving ibrutinib therapy: Results of a comparative performance analysis.接受依鲁替尼治疗的慢性淋巴细胞白血病患者的预后模型：比较性能分析结果
Eur J Haematol. 2021 Mar;106(3):425-427. doi: 10.1111/ejh.13548. Epub 2020 Nov 29.
5
Idelalisib for chronic lymphocytic leukemia.idelalisib用于治疗慢性淋巴细胞白血病。
Clin Adv Hematol Oncol. 2014 Dec;12(12):846-8.
6
Images in Vascular Medicine. Rumpel-Leede phenomenon in a patient with chronic lymphocytic leukemia treated with acalabrutinib.血管医学影像。一名接受阿卡拉布替尼治疗的慢性淋巴细胞白血病患者的鲁姆佩尔-利德现象。
Vasc Med. 2020 Jun;25(3):281-282. doi: 10.1177/1358863X19901166. Epub 2020 Mar 7.
7
The use of ibrutinib in chronic lymphocytic leukemia.依鲁替尼在慢性淋巴细胞白血病中的应用。
Clin Adv Hematol Oncol. 2016 Mar;14(3):154-6.
8
Refractory pure red cell aplasia associated with chronic lymphocytic leukemia successfully treated with ibrutinib.依鲁替尼成功治疗与慢性淋巴细胞白血病相关的难治性纯红细胞再生障碍性贫血。
Leuk Lymphoma. 2017 Feb;58(2):498-500. doi: 10.1080/10428194.2016.1182163. Epub 2016 Oct 18.
9
Resistance Mechanisms to Targeted Agents in Chronic Lymphocytic Leukemia.慢性淋巴细胞白血病中靶向药物的耐药机制。
Cancer J. 2019 Nov/Dec;25(6):428-435. doi: 10.1097/PPO.0000000000000406.
10
Chronic lymphocytic leukemia, autoimmune hemolytic anemia and ibrutinib: a case report and review of the literature.慢性淋巴细胞白血病、自身免疫性溶血性贫血与伊布替尼：一例报告及文献综述
Leuk Lymphoma. 2016;57(3):735-7. doi: 10.3109/10428194.2015.1071489. Epub 2015 Oct 12.
引用本文的文献
1
Zanubrutinib is well tolerated and effective in patients with CLL/SLL intolerant of ibrutinib/acalabrutinib: updated results.泽布替尼在对伊布替尼/阿卡拉布替尼不耐受的慢性淋巴细胞白血病/小淋巴细胞淋巴瘤患者中耐受性良好且疗效显著：最新结果
Blood Adv. 2025 Aug 26;9(16):4100-4110. doi: 10.1182/bloodadvances.2024015493.
2
Pirtobrutinib in Chinese patients with relapsed or refractory B-cell malignancies: A single-arm, open-label, phase 2, multicenter trial.泽布替尼治疗复发或难治性B细胞恶性肿瘤中国患者：一项单臂、开放标签、2期、多中心试验。
Int J Cancer. 2025 Jun 1;156(11):2158-2168. doi: 10.1002/ijc.35339. Epub 2025 Feb 28.
3
Zanubrutinib in Japanese treatment-naive and relapsed/refractory patients with Waldenström macroglobulinemia and CLL/SLL.泽布替尼用于日本初治及复发/难治性华氏巨球蛋白血症和慢性淋巴细胞白血病/小淋巴细胞淋巴瘤患者。
Int J Hematol. 2025 Apr;121(4):483-493. doi: 10.1007/s12185-025-03925-1. Epub 2025 Feb 17.
4
Sustained benefit of zanubrutinib vs ibrutinib in patients with R/R CLL/SLL: final comparative analysis of ALPINE.泽布替尼对比伊布替尼治疗复发/难治性慢性淋巴细胞白血病/小淋巴细胞淋巴瘤患者的持续获益：ALPINE最终对比分析
Blood. 2024 Dec 26;144(26):2706-2717. doi: 10.1182/blood.2024024667.
5
Improved efficacy and safety of zanubrutinib versus ibrutinib in patients with relapsed/refractory chronic lymphocytic leukemia (R/R CLL) in China: a subgroup of ALPINE.在复发/难治性慢性淋巴细胞白血病（R/R CLL）患者中，与伊布替尼相比，zanubrutinib 的疗效和安全性得到改善：ALPINE 的一个亚组。
Ann Hematol. 2024 Oct;103(10):4183-4191. doi: 10.1007/s00277-024-05823-8. Epub 2024 Jun 18.
6
Ibrutinib followed by ofatumumab consolidation in previously untreated patients with chronic lymphocytic leukemia (CLL): GELLC-7 trial from the Spanish group of CLL (GELLC).伊布替尼序贯奥法木单抗巩固治疗初治慢性淋巴细胞白血病（CLL）患者：西班牙CLL研究组（GELLC）的GELLC - 7试验
EClinicalMedicine. 2024 May 25;73:102642. doi: 10.1016/j.eclinm.2024.102642. eCollection 2024 Jul.
7
Zanubrutinib: past, present, and future.泽布替尼：过去、现在和未来。
Blood Cancer J. 2023 Sep 11;13(1):141. doi: 10.1038/s41408-023-00902-x.
8
Zanubrutinib Versus Ibrutinib in Relapsed/Refractory Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma: Interim Analysis of a Randomized Phase III Trial.泽布替尼与伊布替尼用于复发/难治性慢性淋巴细胞白血病和小淋巴细胞淋巴瘤：一项随机 III 期试验的中期分析。
J Clin Oncol. 2023 Feb 10;41(5):1035-1045. doi: 10.1200/JCO.22.00510. Epub 2022 Nov 17.
9
Acalabrutinib in treatment-naive chronic lymphocytic leukemia.阿卡替尼治疗初治慢性淋巴细胞白血病。
Blood. 2021 Jun 17;137(24):3327-3338. doi: 10.1182/blood.2020009617.
10
Pirtobrutinib in relapsed or refractory B-cell malignancies (BRUIN): a phase 1/2 study.泊鲁替尼治疗复发或难治性 B 细胞恶性肿瘤（BRUIN）：一项 1/2 期研究。
Lancet. 2021 Mar 6;397(10277):892-901. doi: 10.1016/S0140-6736(21)00224-5.
本文引用的文献
1
The clinically active BTK inhibitor PCI-32765 targets B-cell receptor- and chemokine-controlled adhesion and migration in chronic lymphocytic leukemia.临床上有效的 BTK 抑制剂 PCI-32765 靶向慢性淋巴细胞白血病中 B 细胞受体和趋化因子控制的黏附和迁移。
Blood. 2012 Mar 15;119(11):2590-4. doi: 10.1182/blood-2011-11-390989. Epub 2012 Jan 25.
2
The Bruton tyrosine kinase inhibitor PCI-32765 thwarts chronic lymphocytic leukemia cell survival and tissue homing in vitro and in vivo.布鲁顿酪氨酸激酶抑制剂 PCI-32765 可阻止慢性淋巴细胞白血病细胞在体外和体内的存活和组织归巢。
Blood. 2012 Feb 2;119(5):1182-9. doi: 10.1182/blood-2011-10-386417. Epub 2011 Dec 16.
3
Biological effects and clinical significance of lenalidomide-induced tumour flare reaction in patients with chronic lymphocytic leukaemia: in vivo evidence of immune activation and antitumour response.来那度胺诱导的慢性淋巴细胞白血病肿瘤 flares 反应的生物学效应和临床意义：免疫激活和抗肿瘤反应的体内证据。
Br J Haematol. 2011 Nov;155(4):457-67. doi: 10.1111/j.1365-2141.2011.08882.x. Epub 2011 Oct 20.
4
The phosphoinositide 3'-kinase delta inhibitor, CAL-101, inhibits B-cell receptor signaling and chemokine networks in chronic lymphocytic leukemia.磷酸肌醇 3-激酶 δ 抑制剂 CAL-101 抑制慢性淋巴细胞白血病中 B 细胞受体信号和趋化因子网络。
Blood. 2011 Sep 29;118(13):3603-12. doi: 10.1182/blood-2011-05-352492. Epub 2011 Jul 29.
5
Optimising the lymphoma response criteria in the era of targeted therapy.在靶向治疗时代优化淋巴瘤反应标准。
Lancet Oncol. 2011 Jul;12(7):616-7. doi: 10.1016/S1470-2045(11)70132-2. Epub 2011 Jun 12.
6
Tumor flare reaction associated with lenalidomide treatment in patients with chronic lymphocytic leukemia predicts clinical response.来那度胺治疗慢性淋巴细胞白血病患者相关的肿瘤 flares 反应可预测临床反应。
Cancer. 2011 May 15;117(10):2127-35. doi: 10.1002/cncr.25748. Epub 2010 Nov 29.
7
Phase II study of dasatinib in relapsed or refractory chronic lymphocytic leukemia.达沙替尼治疗复发或难治性慢性淋巴细胞白血病的 II 期研究。
Clin Cancer Res. 2011 May 1;17(9):2977-86. doi: 10.1158/1078-0432.CCR-10-2879. Epub 2011 Mar 14.
8
The treatment of recurrent/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL) with everolimus results in clinical responses and mobilization of CLL cells into the circulation.依维莫司治疗复发性/难治性慢性淋巴细胞白血病/小淋巴细胞淋巴瘤（CLL）可产生临床缓解，并使 CLL 细胞动员到循环中。
Cancer. 2010 May 1;116(9):2201-7. doi: 10.1002/cncr.25005.
9
Inhibition of Syk with fostamatinib disodium has significant clinical activity in non-Hodgkin lymphoma and chronic lymphocytic leukemia.福他替尼二钠盐抑制 Syk 在非霍奇金淋巴瘤和慢性淋巴细胞白血病中具有显著的临床活性。
Blood. 2010 Apr 1;115(13):2578-85. doi: 10.1182/blood-2009-08-236471. Epub 2009 Nov 17.
10
Lenalidomide treatment promotes CD154 expression on CLL cells and enhances production of antibodies by normal B cells through a PI3-kinase-dependent pathway.来那度胺治疗可促进 CLL 细胞 CD154 的表达，并通过 PI3-激酶依赖途径增强正常 B 细胞产生抗体。
Blood. 2010 Apr 1;115(13):2619-29. doi: 10.1182/blood-2009-09-242438. Epub 2009 Nov 24.
Zotero 插件